Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 13/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | GHSR | Q92847 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930584 | 0.84 | CCR2 (0.62) | CCR2BRAF | |
| SCHEMBL7589363 | 0.81 | RXFP1 (0.61) | CCR2RXFP1GHSRPFKFB3 | |
| SCHEMBL9930918 | 0.81 | CCR2 (0.57) | CCR2PFKFB3BRAF | |
| SCHEMBL9931396 | 0.81 | CCR2 (0.55) | CCR2BRAF | |
| SCHEMBL9930936 | 0.80 | CCR2 (0.67) | CCR2BRAF | |
| SCHEMBL9930594 | 0.78 | CCR2 (0.56) | CCR2GHSRPFKFB3BRAF | |
| SCHEMBL9931543 | 0.77 | CCR2 (0.65) | CCR2BRAF | |
| SCHEMBL9931283 | 0.77 | CCR2 (0.67) | CCR2KDM4EBRAF | |
| SCHEMBL9930692 | 0.76 | CCR2 (0.78) | CCR2BRAF | |
| SCHEMBL9931230 | 0.75 | CCR2 (0.69) | CCR2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2955173-B1 | 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-10-04 | — | — | EP | claimed |
| US-9603834-B2 | 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-03-28 | — | — | US | claimed |
| US-20160228407-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. | 2016-08-11 | — | — | US | claimed |
| EP-2955173-A1 | NOVEL 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2015-12-16 | — | — | EP | claimed |
| EP-2651901-B1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2015-05-27 | — | — | EP | claimed |
| US-20140221351-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-08-07 | — | — | US | claimed |
| EP-2651901-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-23 | — | — | EP | claimed |
| WO-2012082633-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | claimed |
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | claimed |
| EP-2955173-B1 | 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-10-04 | — | — | EP | disclosed |
| EP-2955173-B1 | 1,2-BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9603834-B2 | 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9603834-B2 | 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9603834-B2 | 1,2- bis-sulfonamide derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| EP-2651901-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012082633-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012082633-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228407-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | CCR2 2/4885RXFP1 328/4885GHSR 940/4885 |
| US-20140221351-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | CCR2 2/4885RXFP1 328/4885GHSR 940/4885 |
| US-20120157444-A1 | NOVEL 1,2- BIS-SULFONAMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CXCR2, CCR2, CX3CR1 | CCR2 2/4885RXFP1 328/4885GHSR 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.